Pacira publishes Exparel study results
The study compared the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving Exparel as the base of an opioid-sparing multimodal regimen
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).